影像引导不可逆电穿孔治疗局限性前列腺癌的功能与肿瘤学结局
这项前瞻性研究纳入30例活检证实、未治疗的低至中危局限性前列腺癌患者,于2014年7月至2017年7月接受MRI-经直肠超声融合引导的局灶不可逆电穿孔治疗。中位随访20个月,治疗相关泌尿生殖毒性低,泌尿功能与勃起功能基本稳定,PSA显著下降,6个月靶向活检显示野内治疗失败率为17.9%。
要点
- MRI-经直肠超声融合引导局灶不可逆电穿孔可用于低至中危局限性前列腺癌,泌尿生殖毒性低。
- 12个月时勃起充分可插入比例79.3%、完全控尿率86.2%,与基线无显著差异。
- 6个月多参数MRI联合靶向活检的野内治疗失败率为17.9%(5/28)。
核心结论
- 中位随访20个月,局灶不可逆电穿孔治疗局限性前列腺癌与低泌尿生殖毒性和有前景的肿瘤学结局相关。
研究设计与样本
- 前瞻性研究,纳入30例活检证实、未治疗的低至中危局限性前列腺癌男性(PSA≤15 ng/mL、Gleason评分≤3+4、临床分期≤T2c、多参数MRI病灶≤20 mm),于2014年7月至2017年7月接受MRI-经直肠超声融合引导局灶不可逆电穿孔;主要终点为患者自报问卷评估的泌尿生殖毒性,次要终点为生化、组织学和影像学肿瘤控制指标;采用非参数检验和χ2检验分析。
诊断标准与关键数值
- 基线勃起充分可插入者为83.3%(25/30),12个月为79.3%(23/29),P>.99。
- 基线完全无漏尿且无需尿垫的控尿率为90%(27/30),12个月为86.2%(25/29),P>.99。
- 12个月时ICIQ-MLUTS和IIEF-5问卷变化显示泌尿生殖功能稳定(P=.58和P=.07)。
- PSA中位数由基线8.65 ng/mL(四分位距5-11.4 ng/mL)降至12个月2.35 ng/mL(四分位距1-3.4 ng/mL),P<.001。
- 6个月时28/30例接受治疗后活检,多参数前列腺MRI联合靶向活检确定的野内治疗失败率为17.9%(5/28)。
临床应用与阅片要点
- 阅片时可将局灶不可逆电穿孔治疗区与6个月多参数MRI靶向活检结果对照,关注野内治疗失败(17.9%,5/28)。
- 报告应结合PSA由基线中位8.65 ng/mL降至12个月2.35 ng/mL的变化及泌尿生殖功能问卷结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Irreversible electroporation (IRE) is a nonthermal ablative method based on the formation of nanoscale defects in cell membranes leading to cell death. Clinical experience with the technique for treatment of prostate cancer remains limited. Purpose To evaluate urogenital toxicity and oncologic outcome of MRI-transrectal US fusion-guided IRE of localized prostate cancer. Materials and Methods In this prospective study, men with biopsy-proven, treatment-naive, low- to intermediate-risk prostate cancer (prostate-specific antigen [PSA], ≤15 ng/mL; Gleason score, ≤3 + 4; clinical stage, ≤T2c; lesion size at multiparametric MRI, ≤20 mm) underwent focal MRI/transrectal US fusion-guided IRE between July 2014 and July 2017. Primary end point was the urogenital toxicity profile of focal IRE by using participant-reported questionnaires. Secondary end points were biochemical, histologic, and imaging measures of oncologic control. Analyses were performed by using nonparametric and χ2 test statistics. Results Thirty men were included (median age, 65.5 years); mean PSA level was 8.65 ng/mL and mean tumor size was 13.5 mm. One grade III adverse event (urethral stricture) was recorded. The proportion of men with erection sufficient for penetration was 83.3% (25 of 30) at baseline and 79.3% (23 of 29; P > .99) at 12 months. Leak-free and pad-free continence rate was 90% (27 of 30) at baseline and 86.2% (25 of 29; P > .99) at 12 months. Urogenital function remained stable at 12 months according to changes in the modified International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms, or ICIQ-MLUTS, and the International Index of Erectile Function, or IIEF-5, questionnaires (P = .58 and P = .07, respectively). PSA level decreased from a baseline median value of 8.65 ng/mL (interquartile range, 5-11.4 ng/mL) to 2.35 ng/mL (interquartile range, 1-3.4 ng/mL) at 12 months (P < .001). At 6 months, 28 of 30 participants underwent posttreatment biopsy. The rate of in-field treatment failure was 17.9% (five of 28) as determined with multiparametric prostate MRI and targeted biopsies at 6 months. Conclusion After a median follow-up of 20 months, focal irreversible electroporation of localized prostate cancer was associated with low urogenital toxicity and promising oncologic outcomes. © RSNA, 2019 Online supplemental material is available for this article.
引用
- Collettini F, Enders J, Stephan C, et al. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. Radiology. 2019. PMID: 31161973. doi:10.1148/radiol.2019181987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。